KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Gains from Investment Securities (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Gains from Investment Securities for 14 consecutive years, with -$11000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 100.27% to -$11000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$11000.0, a N/A change, with the full-year FY2025 number at -$11000.0, changed N/A from a year prior.
  • Gains from Investment Securities was -$11000.0 for Q4 2025 at Biolife Solutions, down from $4.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.1 million in Q4 2024 to a low of -$4.7 million in Q4 2022.
  • A 5-year average of -$591937.5 and a median of -$104000.0 in 2021 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 1775.71% in 2022; the steepest drop was 2856.2% in 2022.
  • Biolife Solutions' Gains from Investment Securities stood at -$603000.0 in 2021, then plummeted by 679.44% to -$4.7 million in 2022, then skyrocketed by 137.83% to $1.8 million in 2023, then soared by 129.13% to $4.1 million in 2024, then tumbled by 100.27% to -$11000.0 in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Gains from Investment Securities are -$11000.0 (Q4 2025), $4.1 million (Q4 2024), and -$4.1 million (Q3 2024).